Overview

Addition of Rituximab to Leflunomide in Patients With Active Rheumatoid Arthritis

Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
Combination of rituximab (RTX) with several different chemotherapeutic regimes has proven synergistic effects in patients with either lymphoma or autoimmune diseases. First data of uncontrolled trials with the combination of RTX and leflunomide (LEF) are available.
Phase:
Phase 3
Details
Lead Sponsor:
Frank Behrens
Treatments:
Leflunomide
Rituximab